Routine annual influenza vaccination is recommended for all people aged 6 months and older who do not have a contraindication. The Vermont Immunization Program will provide influenza vaccine for patients age 6 months through 18 years. All vaccines supplied will be inactive quadrivalent preservative-free formulations in prefilled syringes.

The 2018-19 quadrivalent influenza vaccines used in the United States contain an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Singapore/INFIMH-16–0019/2016 (H3N2)-like virus (NEW for 2018-19), a B/Colorado/06/2017-like (B/Victoria lineage) virus (NEW for 2018-19), and a B/Phuket/3073/2013-like (B/Yamagata lineage) virus.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend use of live attenuated influenza vaccine (LAIV) during the 2018-19 season, after not recommending its use the previous two seasons due to concerns about effectiveness against (H1N1)pdm09 viruses during the 2013–14 and 2015–16 seasons. Providers should be aware that the effectiveness of the updated 2017-18 LAIV4 (that was not recommended for use in the United States) containing A/Slovenia/2903/2015 against currently circulating influenza A(H1N1)pdm09-like viruses is not yet known. Efficacy data for last season is expected this fall. For details see the June 8, 2018 MMWR (https://www.cdc.gov/mmwr/volumes/67/wr/mm6722a5.htm?s_cid=mm6722a5_w%20).

For the second year, state-supplied vaccine for pediatric use will include FluLaval, manufactured by ID Biomedical (distributed by GlaxoSmithKline) and licensed for use in individuals 6 months and older. Unlike Sanofi Pasteur’s Fluzone, children age 6 through 35 months receive the same 0.5 ml dose as is used in older children and adults. The dose of FluLaval administered to all ages is 0.5ml.

- FluLaval, 0.5ml presentation, will primarily be supplied to family practices for patients 6 months through 18 years old.
- Pediatric practices will primarily receive the two Sanofi Fluzone vaccines, 0.25ml presentation for patients 6 – 35 months, and 0.5ml presentation for 3 – 18-year-olds.
Injectable influenza vaccine dosing

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Number of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>6–35 months</td>
<td>0.25 mL (Fluzone)</td>
<td>1 or 2</td>
</tr>
<tr>
<td>6–35 months</td>
<td>0.5 mL (Flulaval)</td>
<td>1 or 2</td>
</tr>
<tr>
<td>3–8 years</td>
<td>0.5 mL</td>
<td>1 or 2</td>
</tr>
<tr>
<td>9 years to adult</td>
<td>0.5 mL</td>
<td>1</td>
</tr>
</tbody>
</table>

Concurrent Administration of Influenza Vaccine with Other Vaccines

Inactivated influenza vaccines do not interfere with the immune response to other inactivated vaccine or to live vaccines.

Vaccine Information Statement (VIS)

The Influenza VIS can be found on the CDC website: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.html. The page includes links to VIS translations in many languages.

Please note: The Flu VIS is no longer updated every year. The edition dated 8/7/2015 should be used for the current flu season.

Full ACIP recommendations

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season
https://www.cdc.gov/mmwr/volumes/67/rr/rr6703a1.htm